Royal Bank Of Canada began coverage on shares of Prothena Corporation PLC (NASDAQ:PRTA) in a report issued on Thursday morning, MarketBeat reports. The firm issued an outperform rating and a $87.00 price target on the biotechnology company’s stock.
A number of other brokerages also recently issued reports on PRTA. BidaskClub raised Prothena Corporation PLC from a buy rating to a strong-buy rating in a research note on Wednesday, July 19th. ValuEngine raised Prothena Corporation PLC from a sell rating to a hold rating in a research note on Friday, September 1st. Jefferies Group LLC began coverage on Prothena Corporation PLC in a research note on Monday, July 10th. They issued a buy rating and a $100.00 price objective on the stock. Evercore ISI began coverage on Prothena Corporation PLC in a research note on Wednesday, August 16th. They issued an outperform rating and a $83.00 price objective on the stock. Finally, Oppenheimer Holdings, Inc. reissued an outperform rating and issued a $70.00 price objective on shares of Prothena Corporation PLC in a research note on Thursday, July 6th. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $78.31.
Shares of Prothena Corporation PLC (NASDAQ PRTA) opened at 64.75 on Thursday. Prothena Corporation PLC has a one year low of $40.58 and a one year high of $69.53. The company’s market capitalization is $2.48 billion. The firm has a 50 day moving average price of $59.45 and a 200 day moving average price of $56.23.
Prothena Corporation PLC (NASDAQ:PRTA) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.43. The company had revenue of $26.81 million for the quarter, compared to the consensus estimate of $16.08 million. Prothena Corporation PLC had a negative return on equity of 33.20% and a negative net margin of 527.56%. The firm’s revenue was up 7951.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.18) EPS. On average, equities research analysts predict that Prothena Corporation PLC will post ($4.39) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by Equities Focus and is owned by of Equities Focus. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.equitiesfocus.com/2017/09/17/royal-bank-of-canada-begins-coverage-on-prothena-corporation-plc-prta.html.
In related news, Director Dennis J. Selkoe sold 3,500 shares of the company’s stock in a transaction that occurred on Friday, July 7th. The stock was sold at an average price of $58.11, for a total transaction of $203,385.00. Following the transaction, the director now directly owns 6,345 shares of the company’s stock, valued at approximately $368,707.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Karin L. Walker sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $64.89, for a total value of $324,450.00. Following the transaction, the insider now directly owns 5,000 shares in the company, valued at $324,450. The disclosure for this sale can be found here. 3.10% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of PRTA. Russell Investments Group Ltd. raised its stake in Prothena Corporation PLC by 12.8% during the 1st quarter. Russell Investments Group Ltd. now owns 12,030 shares of the biotechnology company’s stock worth $671,000 after buying an additional 1,369 shares during the period. Bank of New York Mellon Corp raised its stake in Prothena Corporation PLC by 6.4% during the 1st quarter. Bank of New York Mellon Corp now owns 171,970 shares of the biotechnology company’s stock worth $9,594,000 after buying an additional 10,397 shares during the period. Swiss National Bank raised its stake in Prothena Corporation PLC by 31.2% during the 1st quarter. Swiss National Bank now owns 62,300 shares of the biotechnology company’s stock worth $3,476,000 after buying an additional 14,800 shares during the period. Karp Capital Management Corp acquired a new position in Prothena Corporation PLC during the 1st quarter worth approximately $243,000. Finally, Ameritas Investment Partners Inc. acquired a new position in Prothena Corporation PLC during the 1st quarter worth approximately $167,000.
Prothena Corporation PLC Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.